Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532734 | 0.85 | CYP3A4 (0.53) | CA2CA1CA7CA9CA12 | |
| SCHEMBL13518528 | 0.85 | CYP3A4 (0.53) | CA2CA1CA7CA9CA12 | |
| SCHEMBL30459979 | 0.74 | NQO1 (0.68) | CA2CA1CA7CA9CA12 | |
| SCHEMBL441442 | 0.74 | NQO1 (0.68) | CA2CA1CA7CA9CA12 | |
| SCHEMBL29153309 | 0.74 | CYP1A2 (0.56) | CA2CA1CA7CA9CA12 | |
| SCHEMBL14280975 | 0.72 | CA1 (0.55) | CA2CA1CA7CA9CA12 | |
| SCHEMBL21415991 | 0.72 | CA1 (0.55) | CA2CA1CA7CA9CA12 | |
| SCHEMBL17164790 | 0.72 | CA1 (0.55) | CA2CA1CA7CA9CA12 | |
| SCHEMBL7950717 | 0.72 | CA1 (0.55) | CA2CA1CA7CA9CA12 | |
| SCHEMBL5576497 | 0.72 | CA1 (0.55) | CA2CA1CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129102-B1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | US HEALTH (US) | 2025-06-18 | — | — | EP | disclosed |
| US-10738047-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190048001-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2019-02-14 | — | — | US | disclosed |
| US-10131659-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-20 | — | — | US | disclosed |
| EP-3129102-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029424-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | THE US SECRETARY DEPT OF HEALTH (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2015157145-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048001-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | NOX5, CYBB, NOX1 | CA2 3412/4885CA1 3979/4885CA7 3747/4885 |
| US-10131659-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | NOX5, CYBB, NOX1 | CA2 3412/4885CA1 3979/4885CA7 3747/4885 |
| US-20170029424-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | NOX5, CYBB, NOX1 | CA2 3412/4885CA1 3979/4885CA7 3747/4885 |
| US-10738047-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | NOX5, CYBB, NOX1 | CA2 3412/4885CA1 3979/4885CA7 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.